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Species differencesPeroxisomes represent so-called “multipurpose organelles” as they contribute to various anabolic as well as
catabolic pathways. Thus, with respect to the physiological specialization of an individual organ or animal
species, peroxisomes exhibit a functional diversity, which is documented by signiﬁcant variations in their
proteome. These differences are usually regarded as an adaptational response to the nutritional and
environmental life conditions of a speciﬁc organism. Thus, human peroxisomes can be regarded as an in part
physiologically unique organellar entity fulﬁlling metabolic functions that differ from our animal model
systems. In line with this, a profound understanding on how peroxisomes acquired functional heterogeneity
in terms of an evolutionary and mechanistic background is required. This review summarizes our current
knowledge on the heterogeneity of peroxisomal physiology, providing insights into the genetic and cell
biological mechanisms, which lead to the differential localization or expression of peroxisomal proteins and
further gives an overview on peroxisomal biochemical pathways, which are specialized in different animal
species and organs. Moreover, it addresses the impact of proteome studies on our understanding of
differential peroxisome function describing the utility of mass spectrometry and computer-assisted
algorithms to identify peroxisomal target sequences for the detection of new organ- or species-speciﬁc
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Peroxisomes, often attributed as multipurpose organelles, belong
to the basal inventory of eukaryotic cells. General biochemical
functions of peroxisomes are the β-oxidation of fatty acids, etherlipid
biosynthesis, purine degradation and the detoxiﬁcation of hydrogen
peroxide, catalyzed by their most prominent marker enzyme catalase
[1]. In order to meet the speciﬁc metabolic needs of particular
organisms, peroxisomes have modulated their protein composition to
occasionally extreme variations as documented e.g. by the existence
of glycosomes in trypanosomatids, which share common peroxisomal
proteins like the enzymes of β-oxidation or purinemetabolism only as
minor constituents but house enzymes of glycolysis in amounts of upto 90% of the total organellar protein [2]. However, peroxisomes do
not only exhibit signiﬁcant functional differences between individual
species but also within single organisms, contributing to varying
pathways in different tissues. Despite this functional diversity,
peroxisomes share a largely conserved import system for matrix
proteins [3], which means that newly arising peroxisomal constitu-
ents have to acquire corresponding signal sequences during evolution.
Consequently, a variety of peroxisomal proteins can be found
depending on species exclusively in peroxisomes, shared by peroxi-
somes and other organelles or are not peroxisomal at all. Thus, protein
targeting is a ﬁrst regulatory mechanism to acquire functional
heterogeneity. Moreover, the peroxisomal protein composition is
regulated at the expression level; PPARα is a well-known nuclear
receptor controlling the expression of peroxisomal proteins. However,
information on other transcription factors inﬂuencing peroxisomal
genes remains still scarce. Nevertheless, the tissue-speciﬁc response
to peroxisome proliferators [4,5] is an intriguing example that the
transcription of peroxisomal proteins has to be tightly controlled by a
multitude of gene regulators. As a third, substrate afﬁnity of
peroxisomal enzymes can vary between species further modulating
their metabolic capability. This review aims at recapitulating the
present knowledge on the functional diversity of peroxisomes within
the animal kingdom: (1) peroxisomal heterogeneity will be reviewed
in the context of interspecies differences. Examples of mechanisms
leading to functional diversity will be given and discussed in the light
of evolution; (2) in the second part, the specialization of peroxisomal
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relevance of individual pathways in comparison to the well-described
peroxisomal functions in liver; (3) mass spectrometry has given new
impetus to the characterization of organelles; a series of studies has
extended our knowledge on the peroxisomal proteome to a more and
more complete picture. Recent advances with respect to differences in
individual organs/species will be discussed.2. Peroxisomal heterogeneity with respect to species differences
2.1. Peroxisomal import and maintenance
At present, 31 different proteins/genes, so-called peroxins (Pex),
have been discovered, which are required for the biogenesis and
maintenance of functional peroxisomes (Table 1). Many of them are
conserved from lower to higher eukaryotes [6,7]. In mammals/
animals, 14 different peroxins are known (without counting iso-
forms), whereas additional peroxins with nomammalian homologues
have been identiﬁed in one or more yeast species [3,7] implying
functional redundancy (Table 1). Homologs of any of these additional
peroxins have also not been identiﬁed in Caenorhabditis elegans [8].
Themajority of the peroxins are involved in the import of peroxisomal
matrix proteins, which are synthesized on free polyribosomes in the
cytosol. Peroxisomal protein import is best studied in yeast and
mammalian species (Fig. 1). Peroxisomes import fully folded, co-
factor-bound and even oligomeric matrix proteins by the shuttling
receptors Pex5p and Pex7p [9,10]. Pex5p recognizes the vast majority
of peroxisomal matrix proteins by their carboxyl-terminal PTS1 motif
(the tripeptide (S/A/C)-(K/R/H)-(L/M)). The PTS1 has been rede-
ﬁned as C-terminal dodecamers as additional amino acid residues
might inﬂuence the receptor afﬁnity to the cargo protein in a species-
speciﬁc manner [11]. In contrast to plants, very few mammalian
peroxisomal matrix proteins appear to contain an amino-terminal
PTS2 motif (comprised of an N-terminal degenerate nonapeptide (R-
(L/V/I/Q)-xx-(L/V/I/H)-(L/S/G/A)-x-(H/Q)-(L/A)), which is recog-
nized by Pex7p and often cleaved in the peroxisomal matrix [9,12].
Peroxisome targeting signals appear to be distinct and conserved
among eukaryotes. For example, the ﬁrst PTS1, identiﬁed at the C-
terminus of luciferase of the ﬁreﬂy Photinus pyralis [13], is targeted to
peroxisomes in many organisms. In mammals (and plants), the
Pex7p–cargo complex requires Pex5pL, a long isoform of Pex5p
harbouring a Pex7p binding site, as an accessory factor for import; in
contrast, yeast species require Pex18p, Pex21p or Pex20p as accessory
factors for Pex7p [12,14] and have only one (short) Pex5p isoform.
Thus, in mammals (and plants) Pex5p is in charge of sorting both PTS1
and PTS2-containing proteins. Another example for the integration of
a peroxin function in another protein might be a predicted Pex14p/
Pex17p chimeric protein in some fungi [7]. The binding of a cargo to
Pex5p is thought to induce conformational alterations at its N-
terminus, triggering the interaction of the receptor–cargo complex
with the docking/translocation machinery at the peroxisomalTable 1
Presence of peroxins and other proteins in mammals, plants, ﬁlamentous fungi and yeast s
Peroxin function is indicated by color: matrix protein import (blue); membrane assembly (b
of PEX26; 1only found in Yarrowia lipolytica; 2PEX26 is absent in Saccharomyces cerevisia
mitochondrial ﬁssion factor.membrane [10]. The core components of this machinery are Pex13p,
Pex14p and the three Zinc RING ﬁnger proteins Pex2p, Pex10p and
Pex12p (Fig. 1) [9]. The receptors might either translocate fully into
the matrix (“extended shuttle hypothesis”) or remain associated with
the translocation complex (“shuttle hypothesis”). In plants and yeast/
fungi, recycling of cargo-released Pex5p to the cytosol requires Pex4p,
a specialized ubiquitin-conjugating enzyme (E2) that is bound to
Pex22p, and the AAA-ATPases Pex1p and Pex6p [9]. Interestingly,
mammals lack Pex4p (and Pex22p), andmonoubiquitination of Pex5p
is instead mediated by the promiscuous UbcH5 family, speciﬁcally
UbcH5a/b/c (E2D1/2/3) [15]. Furthermore, Pex1p/Pex6p are an-
chored to the peroxisomal membrane by Pex26p in humans but by
Pex15p in Saccharomyces cerevisiae (Fig. 1).
Among all organisms studied so far, only the nematodes C. elegans
and C. briggsae apparently lack PTS2-dependent peroxisomal import
and possess only a single pathway to target matrix proteins to
peroxisomes [8,16]. The C. elegans genome lacks an ortholog of the
PEX7 gene. As a consequence, most proteins that are targeted to
peroxisomes by PTS2 in other organisms are targeted by PTS1 in C.
elegans [16,17]. In addition, only the short isoform of Pex5p is
expressed, which is lacking the Pex7p-interaction motif of the longer
Pex5pL [8]. Therefore, PTS2-containing proteins are not targeted to
peroxisomes in the worm [16,18].
The peroxins Pex19p, Pex3p and Pex16p are involved in
membrane assembly and insertion of peroxisomal membrane
proteins (PMPs) and comprise a relatively simple machinery for
membrane biogenesis in animals, ﬁlamentous fungi and plants [7,9]
(Fig. 1, Table 1). Interestingly, Pex16p appears to be absent from yeast
species (with the exception of Yarrowia lipolytica) and from
Caenorhabditis sp. [8] (Table 1). Those PMPs, which are synthesized
on free ribosomes in the cytosol, contain internal membrane targeting
sequences (mPTS), which comprise a Pex19p-binding site and a
membrane-anchoring sequence (either a transmembrane domain or a
protein binding site) [9]. Pex19p is suggested to function as a cycling
receptor/chaperone, which binds the PMPs in the cytosol and
interacts with Pex3p (and Pex16p) at the peroxisomal membrane
[19,20]. Pex16p might function as a tethering factor for Pex3p, or as
part of the putative membrane-insertion machinery. The three
peroxins received much attention in the last years because a loss of
Pex3p, Pex16p or Pex19p results in the absence of detectable
peroxisomes/peroxisomal membranes, whereas reintroduction
leads to a de novo formation of peroxisomes from the ER [21,22].
Peroxisomes are highly dynamic organelles that increase in
number and size in response to a wide variety of both internal and
external stimuli. In mammals, the three peroxins Pex11pα, Pex11pβ
and Pex11pγ have been implicated in peroxisome proliferation. In
contrast, yeast species only have a single Pex11p but contain several
Pex11p-like proteins and additional peroxins that inﬂuence the size,
number or organization of peroxisomes (Pex23p-Pex25p, Pex27p-
Pex32p) (Table 1). The three mammalian Pex11p isoforms are
supposed to form homo-oligomers, whereas the ﬁve Pex11p isoforms
in plants can interact in hetero-oligomers as well [23,24]. The status ofpecies.
rown); proliferation and division (yellow). PEX9, ORF misidentiﬁed, antisense sequence
e and related yeast species. DRPs, dynamin-related proteins; FIS, ﬁssion factor; MFF,
Fig. 1. Peroxisomal matrix protein import and membrane assembly. Cargo proteins containing the peroxisomal targeting signals PTS1 or PTS2 bind to the corresponding receptors
Pex5p or Pex7p and form receptor–cargo complexes. The Pex7p–cargo complex requires accessory factors for import (Pex5pL, a long isoform of Pex5p, in mammals and plants,
Pex18p, Pex21p and Pex20p in yeast). The receptor–cargo complex in yeast and mammals interacts with a docking site (Pex13p, Pex14p and Pex17p). It is unclear whether the
receptors translocate fully into the matrix (“extended shuttle hypothesis”) or remain associated with the translocation complex (“shuttle hypothesis”). The docking and RING
complexes (the ubiquitin ligases Pex2p, Pex10p and Pex12p) involved in translocation in yeast andmammals are connected by Pex8p in Saccharomyces cerevisiae. Recycling of cargo-
released Pex5p to the cytosol requires Pex4p (or UbcH5a/b/c in humans), a ubiquitin-conjugating enzyme that is bound to Pex22p and the AAA-ATPases Pex1p and Pex6p. Pex6p
binds to Pex15p in S. cerevisiae or to Pex26p in mammals. Membrane assembly and insertion of peroxisomal membrane proteins (PMPs) (containing an mPTS) depends on Pex19p,
Pex3p and Pex16p. Pex19p functions as a cycling receptor/chaperone, which binds the PMPs in the cytosol and interacts with Pex3p at the peroxisomal membrane. Several isoforms
of Pex11p regulate peroxisome proliferation and abundance. Peroxins in grey are only present in yeast/fungi and absent in higher eukaryotes. For further information, see
peroxisome database (http://www.peroxisomedb.org).
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peroxisome abundance. Very recently, phosphorylation of Pex11p in
S. cerevisiae has been demonstrated to regulate peroxisome prolifer-
ation [25].
Mammalian Pex11pβ promotes peroxisomal growth and elonga-
tion, but the division of mammalian peroxisomes is mediated by Fis1p
and the dynamin-like large GTPases DLP1/DRP1 [26]. The tail-
anchored membrane protein Fis1p is the receptor for DLP1 on
peroxisomes (and mitochondria). Furthermore, mitochondrial ﬁssion
factor (Mff) appears to be involved [27]. Interestingly, these three
components are shared by the peroxisomal and the mitochondrial
division machinery in mammals [28,29] (Table 1). Yeast species,
ﬁlamentous fungi and plants also use related dynamin-like GTPases
(DRP3A in plants, Vps1p, Dnm1p in S. cerevisiae) and Fis homologues
to divide peroxisomes and share these components with mitochon-
dria indicating that this is a general conserved principle among
organisms [22,29,30].
In S. cerevisiae, inheritance and motility of peroxisomes to the bud
requires Inp1p and Inp2p. Inp2p is themembrane receptor for the type
5 myosin motor Myo2p on peroxisomes, which drives peroxisomes
along actin ﬁlaments [31]. The GTPase Rho1p binds to Pex25p and is
involved in the recruitment of actin to peroxisomes in S. cerevisiae. By
contrast, mammalian peroxisomes move alongmicrotubules and bind
dynein and kinesin motors by a yet unknown mechanism.
2.2. Purine degradation
Species differences within purine catabolism have been known for
decades, mainly due to the fact, that diverse species degrade purines
stepwise down to alternate excretion products. The principal pathway
existing in ﬁsh, amphibians and many invertebrates is catalyzed by
xanthine oxidase, urate oxidase, allantoinase and allantoicase pro-
ducing the metabolites uric acid, allantoin, allantoic acid and urea as
well as ureidoglycolate [32] (Fig. 2A). Most mammals excrete
allantoin having lost the capability to express allantoinase and
allantoicase; in addition, primates as well as birds and reptiles do
not possess a functional gene for uricase, consequently excreting uric
acid. In parallel to this evolutionary truncation of the pathway several
subcellular reallocations of the corresponding enzymes have oc-curred: potentially, all enzymes with the exception of allantoinase
may have been originally localized in or adjacent to peroxisomes since
throughout eukaryota peroxisomal localizations can be found for
all proteins (Table 2). However, there is a tendency to reallocate
individual enzymes to other compartments potentially to acquire new
cellular functions: e.g. xanthine oxidase, with a peroxisomal localiza-
tion in amphibians and higher vertebrates [33–35] but also insects
[36], was alternatively found to be cytosolic in ﬁshes, primates and
mussels [37–40]. Whereas its association with urate oxidase in
peroxisomes [35,41] may be in line with its function in purine
metabolism, cytosolic xanthine oxidase may also serve cytoprotective
purposes since the reaction product uric acid is a potent radical
scavenger [39]. Thus, evolutionary pressure may favor a cytosolic
location of the enzyme, as the protective effect may outweigh the
drawbacks caused by the spatial separation of individual components
of the pathway. A comparable radiation occurred to the successive
enzymes allantoinase and allantoicase. In most organisms allantoi-
nase localizes to the cytosol or mitochondria [42]; a partially
peroxisomal location was only reported in marine ﬁshes [43]. Thus,
allantoinase may have been originally a cytosolic protein, which
shufﬂed to peroxisomes in the latter. In contrast, allantoicase is
peroxisomal in ﬁshes [44], insects [37] and according to a C-terminal
PTS1 in Amphioxus [45], but in parallel to the emergence of an
allantoinase/allantoicase complex, mitochondrial in amphibians
[44,46]. While at present there is no functional explanation for this
evolutionary redistribution of allantoicase, the increasing spatial
complexity of the purine catabolism may have contributed to the
functional loss of the pathway's last enzymes in higher vertebrates.
Recently, a still actively transcribed gene of mammalian allantoicase
was detected but the protein shows only low allantoate afﬁnities [47].
Thus, the function of this atavistic enzyme remains enigmatic.
2.3. Glyoxylate metabolism
Similar to the phenomena in the purine metabolism, alanine:
glyoxylate aminotransferase (AGT), a key enzyme in oxalate detoxi-
ﬁcation and gluconeogenesis, exhibits two alternative organellar
localizations – peroxisomes and mitochondria – changing rapidly
even among closely related genera [48]. According to a metabolic
Fig. 2. Schematic representation of the pathways of purine catabolism (A), fatty acid β-oxidation (B) and etherphospholipid synthesis (C) in peroxisomes. (B) Peroxisomes can
harbor multiple acyl-CoA oxidases (1-n) with different substrate speciﬁcities (e.g. ACOX1, AXOC2 and AXOC3 in rats). Furthermore, multiple bifunctional proteins (1-n; e.g. L-BP, D-
BP) harbouring both enoyl-CoA hydratase and 3-hydroxy-acyl-CoA dehydrogenase activity as well as different thiolases (e.g. ACAA1, SCPx) have been described. Peroxisomes have
acquired a set of accessory enzymes (e.g. for fatty acid α-oxidation) to transform the acyl-CoA esters of those fatty acids (FA), which cannot directly enter the β-oxidation pathway
(e.g. phytanic acid) [57]. (C) The ﬁrst three steps of etherphospholipid synthesis take place in peroxisomes; synthesis continues in the endoplasmic reticulum (ER). FAR1/2, fatty
acyl-CoA reductases 1/2; DHAPAT, dihydroxyacetone phosphate acyltransferase; ADHAPS, alkyl-dihydroxyacetone phosphate synthase.
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(1) glyoxylate, as a metabolite of glycolate taken up predominantly by
the consumption of plants, is converted to glycine in order to prevent
the emergence of oxalate; (2) glycine and serine accumulating in
protein-rich diets from animal sources can be transaminated to
pyruvate and hydroxypyruvate further subjected to gluconeogenesis
[49]. Whereas the conversion of glycolate to glyoxylate is carried out
by the peroxisomal enzyme glycolate oxidase, gluconeogenesis is a
pathway characteristic for mitochondria. Consequently, AGT was
localized to mitochondria in many carnivores, to peroxisomes in
herbivores and shows a bimodal distribution in omnivorous species
[48]. In mammals a single gene for AGT exists. Thus, it has to encode
either a peroxisomal (PTS) or a mitochondrial targeting signal (MTS)Table 2
Purine degrading enzymes in different species.
Xanthine oxidase Urate oxidase Allantoinase Allantoicase
Invertebrates
Mytilus + (Cyt)
Diptera + (Po) + (Po) + (Cyta) + (?) Po-
Amphioxus Po?
Marine ﬁsh + (Cyt) + (Po) + Po/Cyt + (Po)
Freshwater ﬁsh + (Cyt) + (Po) + Cyt + (Po)
Amphibia + (Po) + (Po) + (Mito) + (Cyt, Mito)
Reptiles + +/– – –
Birds + (Po) – – –
Mammals + (Po) + (Po) – –
Primates + (Cyt) – – –
+gene is present and expressed; intracellular localization in brackets; Po, peroxisomes;
Cyt, cytosol; Mito, mitochondria.
a Gaines et al., Insect Biochem Mol Biol, 34 (2004) 203–214.or both. Rat and marmoset target AGT to peroxisomes and mitochon-
dria by two alternative transcription and translation initiation sites
[50,51]. By onset of translation at initiation site 1, the gene is expressed
with an N-terminal MTS and a C-terminal PTS1, but this translation
product is rather exclusively targeted to mitochondria. Both species
bear an imperfect PTS1 (marmoset KKL, rat NKL) diverging signiﬁ-
cantly from the consensus sequence SKL. Thus, themitochondrial MTS
may provide more efﬁcient targeting information than the PTS. Yet,
gene products, which are translated from site 2, lack the N-terminal 22
amino acids and are consequently imported into peroxisomes. Thus,
an equal distribution of AGT between peroxisomes and mitochondria
is achieved by comparable transcription of the longer and shorter
mRNAs. In humans, rabbits and guinea pigs AGT is exclusively
localized to peroxisomes. Nevertheless, all species bear an ancient
MTS, which is, however, excluded from the open reading frame
because of mutations in translation initiation site 1 [51–53].
Interestingly, in the primary hyperoxaluria type 1 a polymorphism
in the AGT gene (Pro11Leu) in combination with the mutation
Gly170Arg creates a new MTS and the protein is consequently
retargeted to mitochondria in homozygote patients [54]. Two genes
of AGT exist in zebraﬁsh (agxt, Q6PHK4 and agxtl, Q6DG86) showing
62% aa identity.Whereas agxt is translated into a 423 aa sequencewith
a N-terminal MTS, agxtl is translated into a shorter 391 aa sequence
with a potential PTS1 (SRV). Thus, the regulation of the organellar
localization of AGT appears to be organized at the genome level, after
genome duplication in teleosts had generated two versions of AGT. In
summary, the shufﬂing of AGT from mitochondria to peroxisomes in
closely related species is a clear example of how evolutionary pressure
is able to remodel the intracellular localization of individual proteins,
thus creating heterogeneous peroxisomal proteomes.
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The β-oxidation of long and very long chain fatty acids (VLCFA) is
probably the most prominent pathway of peroxisomes and appears to
be present in all vertebrates, invertebrates and protozoans including
the highly specialized glycosomes [55]. Whereas in mammals
(animals) the breakdown of fatty acids is distributed between
peroxisomes and mitochondria, it appears to be exclusively peroxi-
somal in yeast and plants [56]. Since the turnover of fatty acids can
highly depend on the organism's diet and physiological state, it is
coherent to ask if species differences are mirrored in the peroxisomal
β-oxidation pathway. In peroxisomes, β-oxidation is accomplished by
overlapping systems consisting of an acyl-coA oxidase, an enoyl-CoA
hydratase/3-hydroxyacyl-CoA dehydrogenase and a 3-ketoacyl-CoA
thiolase (Fig. 2B). In most mammals, two alternative enzymes carry
out the ﬁrst step, namely ACOX1 preferentially degrading straight
chain fatty acids and ACOX2 with a high afﬁnity for 3-methyl-
branched fatty acids [57]. The second and third steps are achieved by
the D-bifunctional (D-PBE) or the L-bifunctional enzyme (L-PBE): very
long chain (C22-26) and branched chain fatty acids are sequestered
by the D-PBE [58], long chain fatty acids (C16-18) presumably also by
the L-PBE [59,60]. Two enzymes achieve the ﬁnal step of chain
shortening: SCPx (a protein with thiolase activity) for branched chain
fatty acids and the thiolase for others.
Despite the elaborate characterization of fatty acid β-oxidation in
rodents, comparably scarce data exist on possible heterogeneities in
other species. In invertebrates, the key players of peroxisomal β-
oxidation have only been identiﬁed on the protein level for mollusks
[61,62] and the protozoan Tetrahymena [63], but no data on the
enzymatic capacities of these systems are available. Nevertheless, as
indicated by the following example, invertebrate-speciﬁc β-oxidation
systems may be detected in future: ﬁreﬂy luciferase catalyzes the
oxidation of luciferin in peroxisomes of the lantern organ in order to
produce bioluminescence [13]. Recently, however, Oba and coworkers
[64] detected not only signiﬁcant sequence similarities to fatty acyl-
CoA synthetases but showed that the enzyme is still capable to
transmit CoA to fatty acids potentially contributing to a β-oxidation
pathway speciﬁc to ﬁreﬂies. But how is the situation among
vertebrates? Remarkably high β-oxidation capacities have been
reported in peroxisomes of the gerbil, a species with a pronounced
adaptation to hibernation [65]. More information on the basal level of
β-oxidation may be found in studies evaluating the response to
peroxisome proliferators in different species. However, the lack of
extensive comparative studies using variable fatty acid substrates
limits such a comparison to data acquired for the peroxisomal
palmitoyl-CoA catabolism. In mammals peroxisomal capacity to
break down palmitoyl-CoA appears to be high in species, which
simultaneously show a high induction of β-oxidation in response to
peroxisome proliferators. In homogenates, signiﬁcantly high perox-
isomal β-oxidation rates were observed in rat, mice and Syrian
hamster, but much lower ones in guinea pigs and rhesus monkeys
[66,67] (Table 3). These differences may be predominantly attributed
to variations in peroxisome abundance, since the β-oxidation activity
was more similar in isolated peroxisomes, being only twice as high in
rats than in guinea pigs [68]. Physiologically, nutritional preferences
could account for these species differences. However, rats, mice and
guinea pigs are all omnivorous species with a preference to herbal
food. Moyes and colleagues [69] investigated peroxisomal β-oxidation
in rat, hummingbird, herring, dogﬁsh and hagﬁsh, which feed on a
notably different spectrum of fatty acids with varying chain length. No
substrate-speciﬁc variations were detected among these species, but
total peroxisomal β-oxidation in liver exhibited differences. Despite
its nectar based fatty acid-poor diet, the authors observed highest
peroxisomal β-oxidation activities in the hummingbird, whereas
herrings feeding preferentially on polyunsaturated fatty acid-rich
phytoplankton showed surprisingly lower activities. Thus, the
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attributed to the organisms' nutrition seems to be misleading.
Additionally, evolutionary causations should be considered.
2.5. Differential responses to peroxisome proliferators
Peroxisomes are known as organelles adaptable to the speciﬁc
physiological needs of an organism. Hibernating or suckling rats
exhibit signiﬁcantly higher activities of peroxisomal β-oxidation if
compared to rats housed under standard laboratory condi-
tions [70,71], potentially because of increased fatty acid consumption
in the former groups. In addition, feeding of polyunsaturated fatty
acids – preferentially metabolized by peroxisomes – leads to a
considerable peroxisome proliferation in rodents but not in other
species [72,73]. Comparably, different species respond with variable
intensities to synthetic peroxisome proliferators: ﬁbrates, as potent
hypolipidemic drugs, induce peroxisome proliferation [74] and
expression of β-oxidation enzymes [75] but also the formation of
liver tumors in rodents [76] (Table 3). However, the tumor formation
as well as peroxisome proliferation was not detected in humans [77],
exemplifying species differences in peroxisome physiology. The
therapeutic utilization of ﬁbrates against hyperlipidism led to extensive
comparative studies further investigating the species speciﬁcity of
these effects and showed that the massive induction of peroxisome
proliferation and β-oxidation in rats and mice did not hold true for
most species. Other rodents as Syrian hamster and guinea pig showed a
signiﬁcantly reduced reaction upon ﬁbrate treatment [66–68,78–80]
and in the case of guinea pig did not result in any signiﬁcant
peroxisome proliferation (Table 3). Non-rodent mammalians including
primates are also weak responders, with a relatively low increase in β-
oxidation but no signiﬁcant augmentation of peroxisomes
[66,67,79,81–84] (Table 3). In parallel, hepatomegaly and tumor
development were not observed in humans and non-rodent species
(see review by Gonzalez [85]). Amphibians and ﬁshes did also react
weakly upon peroxisome proliferators, showing a slight induction of β-
oxidation but neither peroxisome proliferation nor signiﬁcant hepato-
megaly [86–89]. Birds and the mussel Mytilus galloprovincialis showed
a moderate response to peroxisome proliferators with an increase in
peroxisomes only after long-time exposure or high dosage [90,91]
(Table 3). In summary, massive induction of peroxisomal proliferation
and β-oxidation appears to be a unique feature of Muridae, whereas
other species are more refractory to the treatment. With the detection
of PPARα [92], it became evident that peroxisome proliferators act by
interaction with this nuclear receptor inducing the transcription of
genes for β-oxidation and peroxisome proliferation (e.g. Pex11α). In
1993, Dreyer and colleagues [93] showed that a variety of unsaturated
long chain fatty acids are natural ligands of PPARα, but it remained
uncertain, which parameters contribute to the variability of the
response in different species. Expression experiments with species-
speciﬁc PPARαs and reporter constructs based on the rat PPAR
response element [94–96] did not exhibit substantial differences in
the receptors' afﬁnity to peroxisome proliferators between low and
high responders. However, rats and mice exhibited a one-magnitude
higher expression level of PPARα in liver than humans or guinea pigs
[97,98]; furthermore, humans express up to 50% of an isoform with a
truncated ligand-binding domain. Probably more important for the
insensitivity of primates is their divergent nucleotide sequence in PPAR
response elements. Insertion of the ACOX1 promoters from rat, human
and cynomolgus monkey into reporter plasmids revealed that only the
rat promoter showed responsiveness to PPARα activation [99–101].
Comparably, only a small fraction of the PPAR-responsive genes found
in rat could be induced in human cells [102,103]. This insensitivity may
not solely be caused by variations between rat and human PPARα-
responsive gene elements but also by differences in the receptors'
DNA-binding domain: the development of tumors in ﬁbrate-treated
rats and mice was initially attributed to the increased oxidative stresscaused by the induction of peroxisomal H2O2-producing oxidases
[104]. However, recent studies suggest that a PPARα-dependent
increase in cell cycle control genes such as CDK1-4, PCNA or c-myc
[105,106] contribute to the development of tumors. Yet, in a PPARα-
humanized mouse (human PPARα expressed in a PPARα−/−mouse),
ﬁbrate treatment did not induce tumor growth despite an up-
regulation of peroxisomal oxidases [107]. Thus, the deregulation of
hepatocyte proliferation appears to be a property speciﬁc to the rodent
PPARα. Recently, Shah and coworkers [108] reported that in parallel to
an induction of c-myc, let7c-miRNA was down-regulated in wild-type
but not in humanized mice after treatment with Wy-14,643, a potent
peroxisome proliferator. Overexpression of this micro-RNA decreased
c-myc expression in parallel to an arrest in cellular proliferation. As c-
myc was found to induce hepatocellular proliferation and an increased
incidence of liver cancer in mice [109], the formation of tumors may
indeed be linked to a PPARα-dependent suppression of let7c-miRNA.
Consequently, the species-speciﬁc hepatocarcinogenic effect of perox-
isome proliferators may be due to structural variations in PPARα,
leading to differences in the sparsely characterized gene-suppressive
tasks of this receptor. In summary, the species speciﬁcity does not
appear to be based on a single causality but consists of a complex
interplay between multiple parameters on different regulatory levels.
As the physiological signiﬁcance of peroxisomes in different species is
still far from being completely understood, it is futile to speculate why
the heterogeneous response to PPARα-activators developed in rodents
but not in other species. Nevertheless, the isolated high sensitivity to
peroxisome proliferators in the family Muridae demonstrates that
discrete changes in peroxisomal genes can have an impact on total
physiology of an organism.
2.6. Catalase
In order to remove the nascent H2O2 produced by numerous
oxidases housed in peroxisomes, catalase is usually the most
prominent protein in peroxisomes and hence the classical marker
for the organelle. However, the yeast S. cerevisiae does possess two
genes for catalase, one imported into peroxisomes and one retained in
the cytosol complementing each other in their role in H2O2
detoxiﬁcation [110]. In higher eukaryotes only one gene for catalase
appears to exist. Nevertheless, in sheep [111], guinea pig [112,113]
and the nematode C. elegans catalase [114] is not exclusively localized
to peroxisomes but also to the cytosol. In C. elegans, two genes (Ctl-1,
Ctl-2) exist sharing 82% amino acid identity but diverging signiﬁcantly
near their C-terminus, where only Ctl-2 ends in a PTS1. Both genes
appear to have originated by duplication of a single precursor since
they are localized on the same chromosome in tandem orientation. In
guinea pig, only a single catalase gene exists (A. Völkl, personal
communication), but in vitro translation of total RNA resulted in two
catalase protein isoforms of slightly different size and pI [115]. Thus,
the dual localization may be acquired by alternative splicing. The
existence of a mitochondrial catalase in rodent heart is still critically
discussed [116,117]. As experimental targeting of catalase to
mitochondria in transgenic mice has been reported to increase the
lifespan of the animals [118], the role of catalase in ageing and ROS
metabolism is currently intensely studied [119,120].
As catalase can be found in other locations than peroxisomes, it
may be consistent to ask, if peroxisomes can so radically change their
physiology and proteome, that they lack this prominent enzyme.
Indeed, a catalase gene cannot be found in trypanosomes, despite the
availability of whole genome sequences from several species
[121,122] and hence a glycosomal catalase was not detected at the
protein or activity level [123–125]. Surprisingly, catalase activity as
well as immunoreactivity was also absent in peroxisomes of Sf21 and
Sf9 insect cells [126], possibly indicating that these cells may express
very low levels of this ROS scavenger. Nevertheless, both cell lines
showed signiﬁcant activities in peroxisomal β-oxidation. It will be
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e.g. glutathione peroxidases or peroxiredoxins to protect the cellular
interior from H2O2 emerging from the β-oxidation pathway.
3. Functional role of peroxisomes in different mammalian tissues
3.1. Liver peroxisomes: lipid metabolism, crystalline cores and bile acids
The liver is the most peroxisome-rich organ of the mammalian
body, with peroxisomes comprising approximately 2% of the total
hepatic protein [127]. Consequently, peroxisomes have been ﬁrst
biochemically characterized and speciﬁed as an individual organelle
in this tissue [128]. Due to the high peroxisome concentrations found
in liver homogenates and the possibility to accomplish isolations of
high purity, most of our current knowledge on the organelles'
contribution to metabolic pathways has been derived from liver
peroxisomes. Detailed information on their physiology and enzymatic
content can be found in recent reviews [1,56] and will not be
addressed in this manuscript. Nevertheless, peroxisomes fulﬁll some
tissue-speciﬁc functions which will brieﬂy be speciﬁed. Besides an
elaborate peroxisomal fatty acid β-oxidation system, the liver houses
more unique peroxisomal pathways as, e.g., the synthesis of bile acids.
Initially, the bile acid intermediates DHCA and THCA are synthesized
from cholesterol by two alternative pathways carried out in
mitochondria or the endoplasmic reticulum, respectively (see review
from Ferdinandusse et al. [129]). These precursors are then imported
as CoA-esters into peroxisomes potentially via the ABCD3 transporter
[130]. Inside peroxisomes, the side chain of the C27-bile acid
intermediates are shortened by the enzyme machinery for the
degradation of methyl-branched fatty acids (Fig. 2B). Finally, the
C24-bile acids are conjugated to taurine or glycine by the peroxisomal
enzyme bile acyl-CoA:amino acid N-acetyltransferase (BAAT)
[131,132] and released into the cytoplasm by a yet uncharacterized
transport system. Abnormally increased levels of bile acid intermedi-
ates can be found in peroxisomal biogenesis disorders but also in
single-enzyme defects of AMACR, MFP2 or SCPx. However, the impact
of those intermediates on human health is unclear, as all these
enzymes take part in other peroxisomal pathways [133]. A peroxi-
somal disorder caused by defects in BAAT, as an enzyme speciﬁc to
this pathway, has not yet been described, but studies investigating the
toxicity of the C27-intermediates showed a dose-dependent decrease
in mitochondrial ATP-synthesis and increase in cellular ROS produc-
tion [133]. Besides this direct cytotoxic effect of bile acid inter-
mediates, it has to be considered that the conversion of cholesterol
into bile acids is the predominant route for its removal from the
human body. Thus, peroxisomes have to be regarded of major
importance for the maintenance of cholesterol homeostasis.
In many mammals, urate oxidase appears to be only expressed in
liver (and kidney) where it forms natural crystals in peroxisomes,
thus emphasizing the importance of liver for purine degradation (see
2.2.). Interestingly, peroxisomes in liver exhibit zonal heterogeneity
[134] related to oxygen supply. However, heterogenic peroxisome
populations have also been detected in adjacent hepatocytes or even
inside of single cells, as revealed by the differential staining for various
peroxisomal oxidases [135–138], which may reﬂect specialized
networks of intracellular metabolic signaling.
3.2. Renal peroxisomes: the discovery of microbodies
Besides liver, peroxisomes are most abundant in mammalian
kidney, where they were initially discovered [139]. Generally,
peroxisomes are not equally distributed in this organ but were
found to be conﬁned to the epithelial cells of the proximal tubules
using immunocytochemistry with antibodies against catalase and a
selection of β-oxidation enzymes [140]. However, as shown for other
tissues [141], the use of antibodies against the more generallydistributed peroxins will potentially reveal the presence of peroxi-
somes in other regions of the kidney as well. Renal peroxisomes are
ultrastructurally characterized by the appearance of so-called mar-
ginal plates—plate-like crystalline aggregates beyond the peroxisomal
membrane [142]. Unlike cores marginal plates do not house urate
oxidase but the B-isoform of hydroxyacid oxidase whereas the A-
isoform is found in the matrix in some species [143–145]. Hydro-
xyacid oxidase is expressed in two isoforms from individual genes in
rodents (HAOXA or glycolate oxidase and HAOXB) [146] and three in
humans (HAOX1-3) [147]. Enzymatically, HAOXA/1 preferentially
metabolizes glycolate and other short chain L-α-hydroxyacids,
whereas HAOXB and the two remaining human isoforms prefer
substrates of longer chain length. With regard to tissue-speciﬁc
expression, glycolate oxidase is predominantly found in liver and only
to lesser extents in kidney. HAOXB/2 is more prominent in the latter
organ concentrating in marginal plates [148–150]. The human HAOX3
is another example not only for species speciﬁcity of peroxisomal
proteins but also tissue-speciﬁc expression since it is uniquely
expressed in pancreas [147]. Besides the substrate and tissue
speciﬁcity of these enzyme isoforms, little is known about their
physiological role.
The kidney exhibits high peroxisomal β-oxidation activities, which
are generally much lower in most other tissues [151]. However, the β-
oxidation activity observed was only about half of that found in liver.
In contrast, kidney showed substantially higher dihydroxyacetone
phosphate acyltransferase (DHAPAT) activities for ether lipid synthe-
sis than liver (Fig. 2C). Also, D-amino acid oxidase is an enzyme found
in peroxisomes from both tissues [135,152]. Overall, D-amino acid
activities were found to be much higher in kidney than in liver [153],
where its presence like that of other peroxisomal enzymes is
restricted to the proximal tubule [152,154]. D-Aspartate oxidase, the
second enzyme implicated in the oxidation of D-amino acids, shows a
similar distribution between kidney and liver [155,156]. As for
hydroxyacid oxidases, the physiological role of both peroxisomal D-
amino acid-converting enzymes remains enigmatic. With the excep-
tions of brain, where D-amino acids are actively synthesized and
might act as modulators of glutamatergic receptors [157,158] and
steroidogenic tissue such as adrenal gland and testis, where D-amino
acids are produced in an autocrine or paracrine fashion to stimulate
steroidogenesis [159], these metabolites are not endogenously
produced but only taken up by the ingestion of bacterial ﬂora [160].
Accordingly, the intracellular concentrations of D-amino acids in most
tissues are relatively low and appear incongruous with the compar-
atively high amounts of the enzymes. Thus, it still has to be clariﬁed if
D-amino acid oxidase and D-aspartate oxidase process additional
metabolites in extraneuronal and non-endocrine tissues.
Recently M-LP, a membrane protein with homologies to Pxmp2,
has been localized to peroxisomes [161,162] and showed especially
high expression levels in kidney. However, a subsequent study
localized the same protein to the inner mitochondrial membrane,
where it may be involved in the scavenging of ROS species, produced
by the mitochondrial respiratory chain [163].
In summary, the comparatively larger peroxisomes found in liver
and kidney appear to contain similar but nevertheless signiﬁcantly
different sets of proteins, which imply distinct tissue-speciﬁc
functions. Recently, isolated peroxisomes from both liver and kidney
were characterized inmore detail in several proteomic studies (see 4).
3.3. Peroxisomes of the intestine: up to the tips
Peroxisomes from the small intestine as well as from the colon are
signiﬁcantly smaller than those of liver or kidney (0.1–0.3 vs. 0.3–0.9
µm). Due to this obvious size difference ﬁrst observed by histochem-
istry in guinea pigs, intestinal peroxisomes were termed microper-
oxisomes [164]—a peroxisomal subclass dominating also in many
other tissues. After the development of a ﬁrst successful isolation
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catalase, intestinal peroxisomes house the majority of other perox-
isomal enzymes found in liver, e.g., the major enzymes associated to
fatty acid β-oxidation [166,167], D-amino acid oxidase [165], glucose-
6-phosphate dehydrogenase [168] as well as alkyl-dihydroxyacetone
phosphate synthase (ADHAPS) and DHAPAT taking part in ether lipid
synthesis [169,170] (Fig. 2C). With regard to tissue characteristics of
the intestine, another enzyme of the ether lipid anabolism, the acyl-
CoA reductase, was described [171]; however, as its peroxisomal
localization was only shown for guinea pig, this may be particular to
this species. Usuda and colleagues [172] showed that peroxisomes
from rat liver and intestine might exhibit substantial differences in
their membrane protein composition. Compared to small intestine,
liver peroxisomes house high amounts of the PPARα inducible
PMP26 – presumably Pex11α – and Pxmp2. Pex11α shows highest
expression levels in liver, yet lack of this gene product could be
compensated by non-transcriptional activation of Pex11β or Pex11γ
[173]. Thus, ﬁbrate-induced peroxisome proliferation in the intestine
[166,174] may be a Pex11α independent process as observed in
ﬁbrate-stimulated knockout mice [173]. The lack of Pxmp2 points to
differences in the organelle metabolism, as Pxmp2 was recently
described as an import/export channel for small metabolites [175]. As
the authors point out, other pore forming proteins exist in liver
peroxisomes, which allow a tissue-speciﬁc expression of those
channels thereby acquiring metabolite selectivity in different cell
types. Parallel to the change of the physiologic function of the bowel
from ileum to colon, differences of peroxisomal functions may exist,
e.g., indicated by the high expression of the peroxisomal carnitine
transporter [176] in colon but not in jejunum and ileum [177]. With
respect to a spatial distribution of peroxisomes within the small
intestinal mucosa, peroxisome abundance and enzymatic content
change along the crypt–villus axis in all species investigated [178–
180]. Whereas peroxisomes are only scarcely found in stem cells at
the bottom of the crypt, their number increases continuously towards
the villus tips in parallel to enterocyte differentiation. Peroxisomal
oxidase concentrations increase along with that process indicating a
temporal maturation of the peroxisomal compartment. Yet, a more
detailed reﬂection of tissue-speciﬁc metabolic functions of intestinal
peroxisomes remains difﬁcult since no direct comparative studies
exist so far. Future studies have to deepen our insight on intestine-
speciﬁc peroxisome functions.
3.4. Peroxisomes in the testis: testosterone, fertility and regulated loss
Until recently, peroxisomeswere thought to be exclusively present
in Leydig cells in testis [181]. However, with the development of more
sensitive catalase detection techniques and the use of further
peroxisomal marker proteins peroxisomes were progressively dis-
covered also in Sertoli and germ cells [182–184] as well as in residual
bodies [141]. Using GFP-PTS1 transgenic mice, Nenicu et al. [141]
proved that the germ cells inhabit peroxisomes until the late stages of
spermiogenesis, while they are gradually aggregated into clusters and
completely degraded in the maturing sperm cells. The mechanism
that leads to this disappearance is still unclear. However, Lüers and
colleagues [183] suggested that peroxisomal proteins are more likely
to be selectively degraded than controlled by down regulation of
peroxisome biogenesis.
Although the exact physiological role of peroxisomes in testis is
still enigmatic, their metabolic pathways have to be of vital
importance for normal spermiogenesis since adult patients with the
peroxisomal single-enzyme deﬁciency X-linked adrenoleukodystro-
phy (X-ALD) show impaired spermiogenesis and infertility [185].
These patients have a single-enzyme defect of ABCD1, an ABC
transporter in the peroxisomal membrane, which is presumably
involved in the import of very long chain fatty acids [186].
Comparably, knockout mice for the D-PBE, which also contributes toVLCFA degradation, are infertile with progressive testicular atrophy.
These pathological changes are paralleled by an accumulation of
peroxisomal β-oxidation substrates [184].
Compared to liver, testicular peroxisomes are provided with the
main peroxisomal pathways like β-oxidation or ROS metabolism but
exhibit substantial differences in the abundance of individual proteins
such as catalase or ABCD3 [184]. Furthermore, since testicular tissue is
composed of divergent highly specialized cell types, peroxisomal
protein content in this tissue is heterogeneous, suggesting comple-
mentary or alternative metabolic functions in the different cell types
[141,183]. In this regard, the comparably high levels of catalase found
in Leydig cells [181] may be attributed to a protective role against ROS
during steroidogenesis since this pathway is inhibited by high levels
of H2O2 [187]. Recent studies suggested that testicular peroxisomes
may also play a more direct role in testosterone production. The sterol
carrier protein SCP2/SCPx, generated by alternative transcription
from two initiation sides of the same gene locus, was detected in rat
Sertoli and Leydig cells [188] but not in germ cells. In the Leydig cells,
both SCP2 and peroxisome abundance were increased in response to
an acute luteinizing hormone (LH) stimulus [189]. In contrast,
catalase was not induced by the treatment, suggesting that a speciﬁc
peroxisomal pathway responded to the hormone treatment. Since
these changes preceded a signiﬁcant elevation of serum testosterone
levels, the author concluded that peroxisomes could take part in this
steroidogenic process. In a follow-up publication Mendis-Handagama
[190] monitored intracellular cholesterol as a precursor in testoster-
one biosynthesis in Leydig cells in response to LH stimulation. In
controls, free cholesterol was detected primarily in lipid droplets,
plasma membrane and only occasionally in peroxisomes. However, in
LH-injected rats, many peroxisomes, inner and outer mitochondrial
membranes and some cisternae of SER showed staining for free
cholesterol. Furthermore, some peroxisomes showed spatial relation-
ships to lipid droplets and mitochondria after LH injection. Therefore,
the author suggested that peroxisomes might participate in the
intracellular cholesterol trafﬁcking and delivery into mitochondria,
where testosterone is ﬁnally synthesized. Nevertheless, since the
author did not sufﬁciently discriminate between SCPx and SCP2, it has
to be considered that the enzymatic thiolase domain of SCPx may be
the functional entity involved in steroidogenesis. With regard to
steroidogenesis, it is also interesting, that D-aspartate was found to be
produced in the seminiferous tubules and is capable to stimulate
testosterone production in Leydig cells [159]. Moreover, treatment of
rats with D-aspartate induced the expression of D-aspartate oxidase in
testis tissue [191]. Therefore, steroidogenesis in Leydig cells may be
closely controlled by the expression of different sets of peroxisomal
enzymes.
Signiﬁcant cellular heterogeneities were also reported for the
peroxisomal ABC transporters [141,183], implying the import of
different metabolites into the peroxisomal matrix. The ABC-half
transporters ABCD1 and ABCD3 are highly expressed in Sertoli cells,
whereas ABCD2 shows highest concentrations in Leydig cells. These
heterogeneities in the putative membrane transporters for fatty acid
metabolites may be accompanied by a divergent expression of the
main enzyme subsets for fatty acid β-oxidation. ACOX2, degrading
preferentially branched chain fatty acids, exhibits highest expression
in Leydig cells whereas it was found in signiﬁcantly lower amounts in
Sertoli and germ cells. Additionally, Nenicu and coworkers observed
higher amounts of other enzymes attributed to β-oxidation in Sertoli
cells, a ﬁnding paralleled by the expression pattern of PPARα [192].
Moreover, D-PBE knockout mice show severe disturbances of Sertoli
cell function but not of Leydig cells [184]. Thus, both cell types appear
to metabolize different substrates by divergent subsets of fatty acid β-
oxidation enzymes. With respect to other known peroxisomal
pathways, plasmalogen synthesis appears to be of signiﬁcant
importance for testis physiology, as testis homogenates showed
especially high activities of DHAPAT [151]. Disruption of this key
889M. Islinger et al. / Biochimica et Biophysica Acta 1803 (2010) 881–897enzyme of ether lipid synthesis [193] (Fig. 2C) leads to an arrest in
spermatogenesis and infertility in mice potentially by impeding the
correct formation of the blood–testis barrier.
In maturing sperm progenitors, classical peroxisomal proteins
were generally detected in lower amounts than in somatic cells [141],
implying that peroxisomes play a signiﬁcantly less important role
especially in the later stages of sperm development. However, very
recently two germ cell-speciﬁc peroxisomal residents were reported:
Pxt1 and Ccdc33 [194,195]. Both are highly expressed with the
beginning of the spermatocyte stage of sperm maturation. Thus,
peroxisomes may not be degraded in these cells but may remodel
their proteome to acquire new cell-type-speciﬁc functions.
3.5. Peroxisomes in the heart: ATP and ethanol
Peroxisomes (microbodies) in the myocardium of rodent and
primate species have been described more than thirty years ago
[196,197], and catalase as well as fatty acid β-oxidation enzymes have
been detected by cytochemical and biochemical methods [198].
Strong expression of PeP, a novel peroxisomal protein with a potential
role in myoblast differentiation and development, has also been
detected in heart, brain and skeletal muscle of adult mice [199]. Clear
myocardial peroxisome proliferation and an increase in catalase and
the enzymes of peroxisomal β-oxidation, although signiﬁcantly lower
than in liver, was observed under different peroxisome inducing
conditions and with very different agents (e.g. ﬁbrates as ligands of
PPARα, starvation, experimental diabetes, high-fat diet) [4,116,200–
202]. Moreover, peroxisomal fatty acid β-oxidation has been reported
to contribute substantially to the synthesis of malonyl-CoA, a key
regulator of mitochondrial fatty acid oxidation in the heart, by
providing N50% of the fatty acid-derived acetyl groups that end up in
malonyl-CoA [203]. Thus, peroxisomal β-oxidation may participate in
the control of mitochondrial fatty acid oxidation in the heart.
Importantly, fatty acid oxidation accounts for most of the ATP
generated in the heart, as the organ has a small capacity for both de
novo FA synthesis and storage, thus relying on arterial fatty acid
supply. Deﬁciencies in mitochondrial β-oxidation enzymesmay result
in cardiomyopathy, whereas defects in peroxisomal β-oxidation
enzymes primarily result in neurological complications (see Section
3.7), and cardiac abnormalities have been rarely described in
peroxisomal disorders (e.g. Zellweger syndrome).
Furthermore, the role of catalase in the oxidation of ethanol (by its
peroxidase reaction) appears to be especially important in heart (and
brain), where alcohol dehydrogenase activity is low [204]. A
connection between prolonged alcohol consumption and alterations
in heart (but not liver) peroxisomes was observed 30 years ago
[205,206] in rats fed with ethanol. Considerable peroxisome prolifer-
ation as well as an increase in catalase and acyl-CoA oxidase was
observed accompanied by increased non-enzymatic peroxidation of
membrane lipids [206,207]. Based on inhibition and overexpression
studies, a protective role for catalase in the pathogenesis of alcoholic
cardiomyopathy and alcohol-induced oxidative stress has been
suggested [204,206,208].
3.6. Peroxisomes in the lung: surfactant and ROS
Peroxisomes in the lung were described already 30–40 years ago
in a variety of mammalian species such as mouse, rat, hamster, guinea
pig, rabbit, cat, pig, monkey and man using catalase cytochemistry
[209–211]. In these early studies, catalase-positive peroxisomes were
mainly found in bronchiolar Clara cells and alveolar type II cells
(AECII). The development of more sensitive catalase detection
techniques and the use of additional peroxisomal marker proteins
resulted in the visualization of peroxisomes in all pulmonary cell
types including AECI and alveolar macrophages [212,213] in mice and
man. However, peroxisomes in distinct cell types displayed someheterogeneity with respect to abundance, size and protein composi-
tion indicating functional differences. For example, catalase and
peroxisome size and numbers were high in Clara cells, AECII and
macrophages but low in AECI. In contrast, AECI exhibited higher levels
of β-oxidation enzymes and the lipid transporter ABCD3 (see also
3.7.). In mammalian lung, AECII are especially important for normal
alveolar functioning, as they represent the major source of surfactant
and the progenitors of AECI. Moreover, they can undergo proliferation
and transformation into AECI after cellular injury. Due to the presence
of DHAPAT and SCP2 in AECII peroxisomes [214], these organelles
have been suggested to be involved in the synthesis and/or transport
of the lipid moiety of surfactant, which prevents alveolar collapse on
exhalation of air. Peroxisomal lipid and ROSmetabolismmight as well
be relevant for alveolar macrophages, which are activated by ROS and
secrete lipid mediators of inﬂammation such as leukotrienes and
prostaglandins. They also represent the major source of NO formation
by iNOS in the lung. The inducible form of NO synthetase (iNOS)
was localized to peroxisomes (in hepatocytes) [215]. Moreover,
macrophages and neutrophils produce platelet activating factor, a
plasmalogen depending on peroxisomal ether lipid synthesis
(Fig. 2C). Besides lung, high levels of plasmalogens are also found in
brain, heart and muscle.
3.7. Brain peroxisomes: myelination and neurodegeneration
Inherited peroxisome disorders are predominately characterized
by a more or less severe impairment of the brain structure. Therefore,
peroxisomes appear to play a signiﬁcant role in the physiology of this
most complex organ of the human body [216]. Initially, brain
peroxisomes have been histologically investigated to describe their
spatial and time-dependent distribution. Brain peroxisomes are
signiﬁcantly smaller than those in liver and kidney (0.1–0.2 vs. 0.3–
0.9 µm) and are found in neurons as well as in glia [217]. During rat
development, highest concentrations of peroxisomes occur in the
period between 10 and 16 days after birth [218], which parallels the
onset of neuronal myelination. Comparably, peroxisomes exhibit a
similar population maximum during myelination in humans [219].
Indeed, plasmalogen synthesis, which is initiated in peroxisomes
[220] (Fig. 2C), may represent an extraordinarily important function
in brain [221] (see below). Besides brain, the peroxisomal enzymes
involved in ether lipid synthesis predominate in tissues known to
synthesize wax esters and ether lipids (e. g. sebaceous glands such as
uropygial glands of birds, preputial, meibomian or perianal glands).
Generally, peroxisomes are found in developing neurons in higher
concentrations than in differentiated ones and are enriched at axon
and dendrite terminals, a localization that is not prominent in adult
neurons [222].
With respect to their distribution among different brain regions,
immunostaining against catalase as standard marker enzyme was
used for localization [223,224]. Peroxisomes are found throughout the
brain with the tendency of a higher abundance in brain stem than in
neocortex and cerebellum. Generally, neurons show a size-dependent
staining with large neurons being more intense than small ones.
However, there are exceptionsmirroring the highly complex nature of
this tissue. Immunolabelling of ACOX1 resulted in a staining pattern
comparable to catalase [225]; however, studies on D-amino acid
oxidase [226,227] or D-aspartate oxidase [228] exhibited a differential
distribution, implying the existence of specialized peroxisomal
subpopulations. Interestingly, D-aspartate speciﬁcally accumulates in
the brain and its possible role in native synaptic transmission as an
agonist of glutamate receptors has been reported [229]. In a recent
study, Ahlemeyer and coworkers [230] investigated different brain
regions with series of peroxisomal antibodies. The localization of
various peroxins showed that neurons and astrocytes house more or
less comparable amounts of peroxisomes but exhibit notable
differences in catalase or ABCD3, which were less intensely stained
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cells, which showed very low catalase intensities in this and previous
studies [223], were signiﬁcantly stained with antibodies to Pex14p, a
peroxisomal membrane marker, indicating that brain peroxisomes
may fulﬁl unrecognized functions not associated to H2O2-producing
oxidases.
A straightforward method to categorize the overall spectrum of
CNS-derived peroxisomes would be their puriﬁcation and analysis by
mass spectrometry. However, the heavy myelination of neuronal
tissue has so far prevented their isolationwith sufﬁciently high purity.
Nevertheless, peroxisomes were successfully enriched from brain
homogenates using different isolation protocols [231–233]. These
studies resulted in the localization of themajor peroxisomal pathways
already known from liver in CNS but were not successful in identifying
new brain-speciﬁc pathways. In addition to myelin sheaths, the
broader heterogeneity of peroxisomes from the CNS impedes the
isolation of a standard peroxisome fraction, which covers most
peroxisomes found in this tissue [234], thus emphasizing the
metabolic specialization of different peroxisome subpopulations in
brain. The elucidation of a total-brain peroxisomal proteome remains
a major task for the future, as it will facilitate the discovery of hitherto
undetected peroxisomal pathways, which can be thereafter localized to
speciﬁc brain regions or cell types. Thus, new protocols for the isolation
of brain-derived peroxisomes have to be established, potentially by
combining different experimental approaches as density gradient
centrifugation, immunoisolation and free ﬂow electrophoresis.
Most knowledge on the potential function of brain peroxisomes
was yet discovered by investigating the pathology of peroxisomal
genetic disorders such as X-ALD and Zellweger syndrome or their
genetically engineered counterparts in knockout mice. Impairment of
peroxisomal biogenesis caused by disruption of PEX5, PEX2 or PEX13
(Table 1) disrupts virtually all peroxisomal enzymatic functions,
exhibiting a Zellweger syndrome-like phenotype which is lethal in
early life stages [235–237]. All three knockout mouse models show
neuronal migration and differentiation defects in the cerebral cortex
but also pathologic effects in other brain regions, e.g., cerebellum,
olivary nucleus and spinal cord, and die before birth. Heterozygous
PEX2 knockout mice exhibit widespread lipidosis [238] accompanied
by an elevated level of VLCFA but decreased levels of polyunsaturated
plasmalogens and docosahexaenoic acid (DHA), a potential signaling
molecule in brain development and learning [239]. More distinct
metabolic disturbances are characteristic for peroxisomal single-
enzyme deﬁciencies like X-ALD. Consequently, the elevated VLCFA
levels found in patients with a mutated ABCD1-gene are accompanied
by a less severe phenotype, which in humans mostly develops a lethal
inﬂammatory dismyelinating reaction (commonly at the onset of
puberty but even asymptomatic in brain) [240]. D-Bifunctional protein
(D-PBE) deﬁciency, another single-enzyme defect, causes accumula-
tion of VLCFA in plasma and neuronal tissues [241]. Interestingly, D-
PBE deﬁciency is accompanied by a decrease in the signaling molecule
DHA, which emphasizes the involvement of D-PBE or peroxisomal β-
oxidation in its synthesis [242,243].
In comparison, peroxisomal biogenesis disorders like Zellweger
syndrome are complex diseases, caused by the disturbance of a large
variety of different peroxisomal functions which are presently not
fully elucidated. In this respect, the protective effect of plasmalogens
against accumulated VLCFA is an example for the physiological
crosslinking of different peroxisomal pathways [244], all contributing
to the severe pathology of Zellweger-type disorders. Moreover, the
complete brain pathology is not generated locally in the affected
tissue but is also a consequence of disturbed metabolic functions in
other organs [245]. Thus, conditional PEX5 knockouts in either liver or
brain exhibit neuronal migration defects in the neocortex [246]. Yet,
the Pex5 liver knockout leads to a more severe phenotype at early
postnatal stages, whereas the brain knockout only results in a delayed
formation of brain architecture. Nevertheless, the brain knockoutshows severe dysmyelination and axonal degeneration in the adult
mice, implying organ-speciﬁc peroxisomal metabolic functions [247].
Moreover, brain as a complex tissue consists of a variety of different
cell types, which contribute to the functionality of the whole organ.
Absence of peroxisomes in oligodendrocytes caused a phenotype with
comparable dysmyelination and axonal degeneration similar to
whole brain knockout but at later stages of adulthood [248]. Thus,
peroxisomes in both glia and neurons appear to have a substantial
impact on the maintenance of the architecture and function of the
brain.
Besides inherited disorders, peroxisomes appear to participate in
other human diseases with no direct peroxisomal background:
peroxisomes were found to react on oxidative stress in early
Alzheimer's disease, resulting in an up-regulation of ROS-scavengers
and peroxisome proliferation [249], followed by dramatic peroxisome
impairment during the acute abeta injury [250]. Accumulation of
psychosine—a potential PPARα inhibitor, was paralleled by a decrease
in peroxisomes in the lysosomal storage disorder Krabbe's disease
[251,252]. Thus, the dysmyelination process observed in this
leukodystrophy may be caused by the impairment of peroxisome
homeostasis.
As exempliﬁed in the last paragraph, new peroxisome-associated
disorders may likely be detected in the future, as our hitherto
fragmentary knowledge on peroxisome functions in the brain will be
complemented.
4. Lessons from proteome studies
The ability to simultaneously identify numerous proteins by mass
spectrometry enabled the analysis of the proteomes of whole
organelles. In plants and yeast, mass spectrometry-based proteomics
have expanded the number of peroxisomal proteins to a considerable
degree [253,254]. With regard to the functional signiﬁcance of such
studies, the detection of Rho1p at the membrane of peroxisomes from
S. cerevisae represents one example which resulted in new insights
into the regulation of actin-controlled peroxisomal membrane
dynamics [255].
With respect to the animal kingdom, during the last years, a
considerable number of proteome studies performed on peroxisomes
of mouse and rat liver or kidney have broadened the spectrum of
peroxisomal constituents [60,256–259]. However, most of the
proteins identiﬁed were neither speciﬁc to the organ nor to the
species investigated. As an exception, nudix hydrolase RP2p identiﬁed
in mouse kidney [257] was not found in liver peroxisomes [60,256],
suggesting a tissue-speciﬁc expression. At the transcriptional level
RP2p showed highest expression in kidney but was found at
considerably lower levels in liver [260], whereas the nudix hydrolase
Nudt7 appears to play a more dominant role in the latter [261].
Nevertheless, an exclusive expression of a protein in peroxisomes
from a single tissue appears to be rather infrequent requiring the
assessment of quantitative protein differences.
Identiﬁcation scores or peptide counts from theMS data were used
as an option to estimate the abundance of a protein identiﬁed by MS.
With regard to normalized Mascot identiﬁcation scores, Kikuchi and
colleagues [256] concluded that the ABC transporters ABCD1 and
ABCD2, presumably implicated in the transport of fatty acids across
the peroxisomal membrane, are of minor abundance in liver, whereas
ABCD3 is expressed in high amounts—a ﬁnding also observed by
Islinger et al. [60]. Wiese and coworkers [259] received similar data
frommouse kidney peroxisomes relying on the normalized number of
spectral counts per identiﬁed protein. Thus, ABCD1 and ABCD2may be
of minor functional importance in both tissues and may take part in
pathways with higher signiﬁcance in other tissues, which is in line
with mRNA expression data showing high abundance in lung and
brain [262]. As ABCD1 and ABCD2 appear to be involved in the import
of very long chain fatty acyl-CoAs into peroxisomes [263,264], these
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metabolites in liver and kidney peroxisomes. Since information on
the physiological role of ABCD3 is still scarce, it remains tempting to
identify the substrates predominantly imported by this transporter.
After silencing of ABCD3 in C6 glial cells, Di Benedetto and colleagues
[265] did not ﬁnd a signiﬁcant reduction in the capacity to sequester
VLCFA but observed increased concentrations of hexacosenoic acid
(C26) in the cholesterylester fraction. A partial functional overlap
between both peroxisomal ABC transporters, as suggested by
Braitermann and coworkers [266], could explain such a phenomenon.
Reliable information should result from direct quantitative compar-
ison of peroxisomes from different sources. Mi and coworkers [267]
conducted a quantitative proteome analysis of mouse peroxisomes
from liver and kidney based on 2D-IEF/PAGE and Maldi-TOF mass
spectrometry. Discrete differences were found for enzymes involved
in fatty acid β-oxidation: in liver, SCPx was strongly enriched, which
may be attributed to its reactivity towards the metabolites DHCA and
THCA [268], intermediates in the liver-speciﬁc pathway of bile acid
synthesis. Alternatively, SCPx could be involved in the α-oxidation of
phytanic acid, where it may act as a solubilizing agent for phytanoyl-
CoA similar to its shorter variant SCP2 [269]. Notably, 2-hydroxyphy-
tanoyl-CoA hydroxylase, the key enzyme of this pathway, exhibited
also higher abundance in liver than in kidney. In addition to the
kidney-speciﬁc Nudix hydrolase RP2p, ACOX1 and L-PBE showed
considerably higher expression rates in kidney than in liver. Since L-
PBE is obviously not involved in the breakdown of very long chain and
branched chain fatty acids but may contribute to the degradation of
dicarboxylic acids [270] or long chain fatty acids [59], these pathways
have to be considered of signiﬁcant importance in kidney. With the
development of more sensitive mass spectrometers and reagents for a
direct quantiﬁcation of peptide amounts, quantitative proteome
studies will be also applicable in tissues with low peroxisome
abundance or for the characterization of peroxisomal subpopulations
within a single tissue [138]. According to these examples, quantitative
proteomics promises to be a valuable technique, which certainly has
to be validated by the appropriate cell biological and biochemical
methods.
Proteome studies analyzing peroxisomes from non-rodent animal
species were so far only carried out for the mussel digestive gland and
trypanosomatids [123,271,272]. In case of mollusks, only a small
fraction of the analyzed spots could be identiﬁed since the genome
sequence of this species is at present not available. Thus, the authors
resided to identify selected proteins by immunoblots, which therefore
did not result in the detection of new species-speciﬁc proteins. In
glycosomes of Trypanosoma brucei, the proteomic analysis mirrored
the physiological uniqueness of these specialized organelles detecting
mainly glycosome-speciﬁc enzymes from pathways such as glycolysis,
pentose phosphate pathway, pyrimidine biosynthesis and purine
salvage. Proteins from peroxisomal pathways like etherlipid synthesis
or degradation of peroxides were only detected in very moderate
numbers outlining their minor importance in these organelles.
Importantly, the authors were not able to identify enzymes
contributing to the pathway of fatty acid β-oxidation. Nevertheless,
glycosomes share the membrane-spanning ABC transporter ABCD1
(PMP70) with peroxisomes [123], suggesting a role in the transport of
other metabolites across the organelle's membrane [273]. Despite
these major enzymatic differences between glycosomes and peroxi-
somes, the presence of the major peroxins at the membrane of
glycosomes was conﬁrmed, outlining the parallels in organelle
biogenesis. In addition, the identiﬁcation of numerous previously
unassigned proteins partially bearing a PTS1 signal may increase the
number of glycosome-associated functions.
Computational approaches to detect cellular targeting sequences
may offer an alternative to determine the overall peroxisomal protein
composition in the theoretical transcriptome of an organism. In case
of thewell-deﬁned PTS1, several computer algorithms have been usedand led to the identiﬁcation of new peroxisomal candidates.
Kurochkin and coworkers [274] identiﬁed 29 potentially peroxisomal
genes screening rodent and primate GenBank databases for a PTS1.
One of them, Tysnd1, was subsequently experimentally characterized
as a novel peroxisomal protease involved, i.e., in the cleavage of the N-
terminal PTS2 after peroxisome import [275]. Three PTS1 prediction
programs were developed by computer-assisted learning strategies,
namely PTS1-predictor [276], PeroxiP [277] and PTS1-prowler [278].
Emanuellson and colleagues [277] used PeroxiP to detect 430
peroxisomal candidate genes in 8 species, identifying several
orthologs of mammalian peroxisomal proteins in invertebrates, but
did not conﬁrm their localization in experiments. Hawkins et al. [278]
applied PTS1 prowler for the search on unknown peroxisomal
proteins in a RIKEN IPS7 mouse data set and found 48 candidates.
Arbitrarily, the localization of ﬁve candidate genes was validated with
three turning out to be true peroxisomal residents. Thus, at the
current stage, computer-based PTS1-prediction software is applicable
for the search for new peroxisomal candidates but is still too error
prone to stand alone without thorough experimental veriﬁcation. In
an attempt to expand database mining upon PTS2-targeted proteins,
Mizuno and coworkers [279] used an approach similar to the method
described for PTS1 sequences [274]. However, none of the experi-
mentally validated candidates localized to peroxisomes. Hence,
without integrating further experimental data, computer algorithms
predicting potential PTS2 signals are highly inaccurate and are not
suitable to search for unknown peroxisomal constituents.
5. Concluding remarks
As recapitulated in this review, peroxisomes have acquired distinct
specializations to adapt to the speciﬁc physiological demands of a
species or organ. In this context, peroxisomes share the basic set of
proteins required for biogenesis and homeostasis and as far as we
know a bulk of enzymatic functions such as fatty acid β-oxidation or
removal of ROS. Nevertheless, our current view on peroxisomes is
biased by immunological detection methods using antibodies against
widely distributed proteins. However, recent studies using GFP-
labeled transgenes or antibodies against Pex-proteins showed that
peroxisomes do also exist in cells and tissues where catalase or β-
oxidation enzymes could not be identiﬁed. Therefore, our current
knowledge on peroxisomal variability is possibly just its beginning,
and future research will give rise to hitherto unknown peroxisomal
functions. Hence, more sophisticated technologies to purify peroxi-
somes from complex tissues like brain for subsequent proteomic
characterization and microscopic methods to unravel the spatial
distribution of peroxisomal subpopulations in a cell will certainly
expand our understanding of peroxisomal complexity during the next
decade.
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